medigraphic.com

2011, Number 4

<< Back Next >>

Rev Med MD 2011; 2.3 (4)

Immune response to Bacille Calmette-Guerin (BCG) as bladder cancer treatment

Bravo-Gálvez VM, Ríos-Ibarra LP

Language: Spanish
References: 25
Page: 216-218
PDF size: 537.19 Kb.


ABSTRACT

The Bacille Calmette-Guerin (BCG) has been employed as adjuvant therapy in the urinary bladder cancer treatment. Different theories have attempted to explain the benefit of BCG on this illness, the most outstanding takes into consideration a local immune phenomenon possibly mediated by anti BCG cell specifically. According to this theory, this phenomenon unleashes a flow of events that determines a systemic immune reaction, where it is indispensable for such activation, the presence of the phagocyte myco-bacteria antigen by macrophage-monocytes or dendritic cells to the T helper cells (TH cells). The tumor cells have BCG infected phagocytes characteristics, simulating being activated cells, thus the interaction between BCG and tumor cells is an immune response mediated by phagocytes. Adding BCG to the vesical wall through the fibronectin pathway has exhibited to be an important step to the antitumorigenic activity. The time for the response is variable and can reach a six months period after the instillation.


REFERENCES

  1. Registro Histopatológico de Neoplasias Malignas de México 2001. Secretaría de Salubridad y Asistencia. Estados Unidos Mexicanos.

  2. Böhle A, Leyh H, Frei C, Kühn M, Tschada R, Pottek T, Wagner W et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomized, double-blind, placebo-controlled phase III multicentre study. Eur Urol Sep 2009;56(3):495-503.

  3. Kaufman J. Tyagi V, Anthony M, Chancellor MB, Tyagi P. State of the art in intravesical therapy for lower urinary tract symptoms. Reviews in Urology 2010; 12(4): 181-189.

  4. García Rodríguez J, Fernández Gómez JM, Escaf Barmadah S, González Alvarez RC, Rodríguez Robles L, Miranda Aranzubia O. Factores pronósticos en la recidiva y progresión del cáncer superficial vesical. Grupos de riesgo (Parte I).Actas Urol Esp. 2006;30(10):998-1008.

  5. Okamura T, Akita H, Imura M, Kaneko T, Mizuno K, Tozawa K, Kohri K. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatmen t . int. J Urol 2008; 15(11):976-980.

  6. Lerner P, Tangen CM, Sucharew H, Wood D and Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette-Guérin for high risk Ta, T1 bladder cancer. J Urol May 2007;177: 1727-1731.

  7. Cumisky S. BCG immutherapy for carcinoma of the urinary bladder. Nurs Stand. 2000; 14(37): 45-47

  8. Morales A. Treatment of carcinoma in situ of the bladder with BCG a phase II trial. Cancer Inmunology and Inmunotherapy 1980; 9:69-72.

  9. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. Guidelinies on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59(6): 997-1008.

  10. Prescot S. Mechanisms of action of intravesical BACILLE Calmette-Guérin: local immune mechanisms. Clin Infect Dis 2000; 31 (suppl3): 91-93.

  11. Brandau S. In vitro generation of bacillus Calemet-Guérin-activated killer cells. Clin Infect Dis 2000; 31 (Suppl 3): 94-100.

  12. González O. Spectrum of bacilli Calmete-Guérin (BCG) infection alter intravesical BCG immunotherapy. Clin Infect Dis 2003; 36: 140-148.

  13. Rattlif TL. Role of animals models in understanding intravesical therapy with bacilli Calmette-Guérin. Clin Infect Dis 2000; 31(suppl3):106-108.

  14. Agarwal A, Agrawal U, Verma S, Mohanty NK, Saxena S. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post –intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 2010; 32(2):348-356.

  15. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon gamma as the lymphokine that activates human macrophage oxidative metabolism and anti-microbial activity. J Exp Med 1983; 158: 670.

  16. Hawkyard S, James K, Prescott S, Jackson AM, Ritchie AW, Smyth JF, Chisholm GD. The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol 1991; 145: 1078.

  17. Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 1990;144: 59.

  18. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin mediated bacilli Clamette-Guerin attachment to murine bladder mucosa: requirement for expression of an antitumor response. J Clin Invest 1990; 85: 62.

  19. Content J, de la Cuvellerie A, De Wit L, Vincent-Levy-Frébault V, Ooms J, De Bruyn J. The genes coding for the antigen 85-complex of M. tuberculosis bovis BCG are members of a gene family: cloning, sequence determination and genomic organization of the gene coding for the antigen 85C of M. tuberculosis. Infect Immun 1991; 59: 3205.

  20. Fleischmann JD, Park MC, Hassan MO. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette_guérin therapy. J Urol 1993; 149(2): 268-271.

  21. Teppema JS, de Boer EC, Steerenberg PA, van der Meijden AP. Morphological aspects of the interaction of bacillus Calmette-Guérin with urothelial bladder cells in vivo an in vitro:relevance for antitumor activity? Urol Res 1992;20:219-228.

  22. 22.de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Clamette-Guerin for superficial bladder cancer: processing, stability an prognostic value. J Urol 1996; 155:477-482.

  23. Pang A. Morales A. BCG induced murine peritoneal exudates cells: cytotoxic activity against a syngeneic bladder tumor cell lineJ. Urol 1982; 127: 1225-1229.

  24. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ. Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and natural killer activity. Cancer Res 1983;43(4):1611-1615.

  25. Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H,et al. Systemica immune response after intravesical instillation of bacilli Calmette-Guérin (BCG) for superficial bladder canCcer.l in Exp Immuno l 1999; 115: 131-135.




2020     |     www.medigraphic.com